Tespa1 negatively modulates asthmatic attack is associated with IL-4/STAT-6 pathway of mast cell

Ruhui Yang  
Ru-hui Yang, Ph. D. of Pharmacology, Associate professor. Department of Pharmacology, College of medicine and health, Lishui University, Lishui, 323000, China

Guangli Wang  
Guangli Wang, Experimentalist of Immunology, College of Medicine and Health, Lishui University, Lishui, 323000, China

Lingyun Li  
Clinical Laboratory, Lishui People's Hospital, Lishui, 323000, China

Hanjiang He  
Hanjiang He, Professor of Immunology, College of Medicine and Health, Lishui University, Lishui, 323000, China

Mingzhu Zheng  
Mingzhu Zheng, Doctor of Immunology, Program in Molecular and Cellular Biology, Zhejiang University School of Medicine, Hangzhou 310058, China

Linrong Lu  
Mingzhu Zheng, Doctor of Immunology, Program in Molecular and Cellular Biology, Zhejiang University School of Medicine, Hangzhou 310058, China

Songquan Wu  
Songquan Wu (✉️ zjlswsq@163.com)  
Lishui University  
https://orcid.org/0000-0002-8570-6912

Research

Keywords: Tespa1, Asthma, Mast cell, STAT6

DOI: https://doi.org/10.21203/rs.3.rs-31181/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background Thymocyte-expressed, positive selection-associated 1 (Tespa1) is a critical signaling molecule in thymocyte development. This study aimed to investigate the regulatory effect of Tespa1 on mast cells in the pathogenesis of asthma and its relationship with the interleukin (IL)-4 /signal transducers and activators of transcription 6 (STAT6) signaling pathway.

Methods Tespa1 mRNA expression analysis and IgE levels were carried out using the induced sputum of 33 adults with stable asthma and 36 healthy controls. Tespa1- knockout mice (Tespa1 -/- , KO) and C57BL/6 background (wild-type, WT) mice were sensitized and treated with ovalbumin (OVA) to establish an asthma model. Pathological changes, number and activity of mast cells, and changes in activity of the IL-4 /STAT-6 pathway in lung tissue were detected. The changes of enzyme activity and STAT6 activity after mast cell gene knockout were analyzed in vitro. The association between the Tespa1 and P-STAT6 was analyzed by immunoprecipitation method.

Results Compared with the healthy controls, Tespa1 expression was decreased, and IgE levels were elevated in the sputum of asthmatic patients. Animal experiments showed that Tespa1 -/- mice exhibited more severe inflammation, higher quantity of goblet cells and mast cells in the bronchium, and greater activity of mast cell tryptase, which is induced by ovalbumin, than WT mice. And IL-4, IL-13, phospho-Janus kinase 1, and P-STAT6 expressions presented a higher increase in the Tespa1 -/- mouse model than in the WT mouse model. Further in vitro studies confirmed that IL-4 could more significantly promote tryptase and P-STAT6 activities in Tespa1 -/- mast cells than their WT counterparts. Correlation analysis results showed a negative correlation between Tespa1 and P-STAT6. Immunoprecipitation results showed a direct link between Tespa1 and P-STAT6.

Conclusions Altogether, our results indicate that Tespa1 can negatively regulate mast cell activity, and this event is related to the mast cell IL-4/STAT6 signaling pathway and could be therapeutically exploited to treat asthma attacks.

Background

Mast cells play an important role in the innate and adaptive immunities related to the pathophysiologic process of asthma. Mast cells not only act as effector cells during allergic reactions, but also perform a complex role in the induction and regulation of adaptive immune responses of asthma [1–3]. When an allergen enters the atopic patient, IgE is specifically synthesized by B lymphocytes and bind to the high-affinity IgE receptor (FceRI) on the surface of mast cells and basophils [4, 5]. If the allergen re-enters the body, it can bind with IgE FceRI on the mast cells, thus promoting cell activation, synthesizing and releasing various active mediators, such mediators as histamine, chemokine, neutrophil chemokine, prostaglandin [6, 7]. These mediators and cytokines play a pivotal role in the pathogenesis of asthma and inflammation. Interleukin (IL)-4 and IL-13 are among the cytokines produced by mast cells. IL-4 is the first
cytokine shown to be produced by mast cells. IL-4 production in mast cells has been studied in relation to IgE-mediated activation [8, 9]. IL-4 is a pluripotent cytokine that plays an important role in inducing allergic Th2-type immune responses [10]. IL-4 activates signal transducers and activators of transcription 6 (STAT6) and induces the expression of IL-4–inducible genes, including class II major histocompatibility molecules, low-affinity IgE receptor, and IL-13 [9, 11]. Therefore, IL-4/STAT6 signaling plays a central role in the participation of mast cells in asthma progression.

Thymocyte-expressed, positive selection-associated 1 (Tespa1) is a critical signalling molecule in thymocyte development [12]. Tespa1 is highly expressed in mast cells and is involved in the negative regulation of mast cell activation and mediation of allergic reactions by negatively regulating FcεRI-mediated signaling [13]. However, the role of Tespa1 in the IL-4/STAT6 signaling pathway, an important pathway for mast cell function and asthma pathogenesis, remains unclear.

In this study, we observed that Tespa1 is associated negatively with the IL-4/Stat-6 signaling pathway in the activation of mast cells, thus providing a new intervention target for mast cells in the pathogenesis of asthma.

**Materials And Methods**

**Detection of Tespa1 mRNA expression in the sputum of asthma patients and healthy controls.**

Tespa1 mRNA expression analysis was carried out using the induced sputum of 33 adults with stable asthma and 36 healthy controls. All subjects were recruited from the Respiratory Clinic of Lishui People's Hospital, Lishui, China. The Global Initiative for Asthma guidelines (www.ginasthma.org) were used by a respiratory medicine specialist to diagnose asthma. Total RNA was extracted from the induced sputum samples by using the TRIlzol reagent (Invitrogen, U.S.A) according to the manufacturer's instructions. All sputum samples were processed with RNAProtect cell reagent and phosphate-buffered saline (PBS) according to the manufacturer's instructions. An IQ SYBR Green SuperMix polymerase chain reaction (PCR) array kit was purchased from Bio-Rad (USA). Two micrograms of extracted RNA was converted to cDNA by Moloney murine leukemia virus reverse transcriptase (Fermentas, CAN), which was used according to the manufacturer's instructions. The cDNA was amplified using the following forward and reverse primers: forward: 5′-CAACCATCCAAC ACT GATGTGCC-3′ and reverse: 5′-TCCAACACAA CTTGGTCCAAA; for β-actin, forward: 5′-TGACGTGGACATCCGCAAAG-3′ and reverse: 5′-CTGGAAGGTG GACAGCGAGG-3′. The human β-actin housekeeping gene was used as an internal control. The primers were designed and synthesized at Shanghai Generay Biotech (Shanghai, China). The reaction was evaluated using a CFX Connect Real-Time PCR system (Bio-Rad, USA). The relative expression levels of the mRNA in each sample were calculated by normalizing the threshold cycle (Ct) value to the Ct value of the β-actin housekeeping gene by using the 2^ΔΔCt method. The mRNA expression levels were expressed in arbitrary units.

**IgE enzyme-linked immunosorbent assay (ELISA)**
The sputum was collected in a plastic container, and homogenized by adding an equal volume of 1% dithiothreitol for 30 min at room temperature. After incubation, the supernatant was centrifuged at 2000 r/min for 10 minutes, and the sputum IgE levels were tested using the Human IgE ELISA Kit (EK175 - 96, MultiSciences, China) as previously described [14]. Samples measurements were obtained at 450 nm by using a SpectraMax Plus 384 microplate reader (MD, U.S.A) and SoftMax Pro software.

**Animal and mouse models of acute asthma**

*Tespa1*-knockout mice (*Tespa1* /KO) and C57BL/6 background (wild-type, WT) mice were generated via homologous recombination-mediated gene targeting at the Shanghai Research Center for Model Organisms as previously described [13]. The mice were housed in a temperature-controlled room under a 12 h dark/light cycle and were allowed access to food and water ad libitum. This study was conducted in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and its protocol was approved by the Animal Research Ethics Board of the Lishui University (Lishui, Zhejiang Province, China. Permit Number: 0901-2018).

*Tespa1* /KO mice and WT mice were divided into two groups (15 mice per group), namely, the control and asthma groups. The asthma mouse model was established using a traditional protocol [15, 16]. Briefly, allergic asthmatic reactions and airway remodelling were induced in the abovementioned mice by using chick ovalbumin (OVA, Sigma, U.S.A). Specifically, the mice were initially sensitized through intraperitoneal (i.p.) injections of PBS with 25 μg OVA in 1 mg aluminium hydroxide gel (Thermo Scientific Inc., Germany) and in 0.2 mL PBS, at pH 7.4, on days 0, 7, and 14. The mice were subsequently randomized into groups that were repeatedly administered nebulized with 5% OVA in PBS or PBS alone by using an ultra-sonic nebulizer with an aerosol chamber (Yuyue Medical Equipment & Supply Co., Ltd., Shanghai, China) on days 15 to 42. The drug was administered for 30 min each day for 28 consecutive days. The mice in the control group were i.p. and atomized with equal volume of PBS.

**Measurement of airway resistance**

On day 42, nine mice from each group were anesthetized via i.p. injections of 300 mL pentobarbital sodium (60 mg/kg) before undergoing tracheostomy tube insertion. Airway resistance and compliance measurements were performed using a FinePointe RC system (Buxco Research Systems, Wilmington, NC). The mice were subsequently challenged with aerosolized PBS (baseline) acetylcholine treatment doses of 0, 1, 2, 4, 8, and 16 mg/mL. Average compliance values were recorded during a 3 min period following each challenge [17].

**Measurement of IL-4 and IL-13 protein expressions by ELISA**

Bronchoalveolar lavage fluid (BALF) was centrifuged at 1,000 × g for 5 min at 4 °C. After centrifugation, the IL-4 and IL-13 protein expression levels in the BALF supematant were measured using a sandwich ELISA kit (70-EK204, 70-EK213, MultiSciences, China) according to the manufacturer’s instructions.
Samples measurements were obtained at 450 nm by using a SpectraMax Plus 384 microplate reader (MD, U.S.A) and SoftMax Pro software.

**Lung histology**

For the histological evaluation of mouse lung tissue specimens, we fixed the left lung of each mouse in 10% buffered formalin. The fragments were then dehydrated, cleared, and embedded in paraffin. The whole lung was serially sectioned (3 - 4 μm-thick), stained with H&E for pathological analysis, and stained with periodic acid-Schiff (PAS) for goblet cell detection. The degree of peribronchial and perivascular inflammation was evaluated according to a subjective scale ranging from 0 to 4 [18, 19]. The degree of cell infiltration in the above tissues was scored as follows: 0, no cells; 1, a few cells; 2, a ring of cells with a depth of one cell; 3, a ring of cells with a depth of two to four cells; 4, a ring of cells with a depth of more than four cells. Reticular basement membrane thickness was measured by image analysis of multiple randomly selected tissue sections, with each of section comprising 30 analysis points, by using an Olympus software microscope system. Repeat measurement error was assessed by performing multiple measurements on a single membrane area in four subjects, as previously described [20].

The degree of goblet cell hyperplasia in the airway epithelium was quantified in accordance with the following five-point system: 0, no goblet cells; 1, <25% of the cells in the epithelium are hyperplastic; 2, 25%–50% of the cells in the epithelium are hyperplastic; 3, 50%–75% of the cells in the epithelium are hyperplastic; and 4, >75% of the cells in the epithelium are hyperplastic. Five randomly distributed left lung airway sections were analyzed in each mouse, and the average score was calculated by summing the scores from the five fields.

Mast cells were stained with toluidine blue. The sections were stained with 1% toluidine blue (Sigma-Aldrich) solution in 1% sodium chloride with diluted 1:10 for 10 min, washed for 1 min, differentiated with 0.5% glacial acetic acid for several seconds, and washed for 5 min. Mast cells were identified by metachromatic staining of their granules. The stained slides were all quantified under identical light microscope conditions, in terms of magnification, gain, camera position, and background illumination [21, 22].

**Immunofluorescence and horseradish peroxidase (HRP)-diaminobenzidine immunohistology**

For immunofluorescent staining, sections of lungs or cells were incubated with the antibody against mast cell tryptase (ab2378, Abcam, UK), Tespa1 (R1309-16, HuaAn Biotechnology, China), P-STAT6 (ab263947, Abcam, UK) and DAPI (4′,6-diamidino-2-phenylindole, Life Technologies,), and images were obtained by using a confocal laser scanning microscope (LSM 880, Zeiss). The protein expression levels were analyzed using Image J.1.44 software.

For immunohistochemical staining, the slides were incubated with 3% H₂O₂ for 10 min after dewaxing, and then washed with PBS for 5 min at room temperature. Antigen retrieval was performed in citrate buffer (pH 6.0) by microwave heating, and blocking was performed with 10% non-immune goat serum for
30 min after cooling. The slides were incubated with an antibody against mast cell tryptase (ab2378, Abcam, UK) overnight at 4 °C. After rinsing with PBS, the sections were incubated with the HRP-conjugated secondary antibody (Maixin, Fuzhou, China) for 30 min at room temperature. Hematoxylin was applied as a counterstain. Eight fields were randomly selected for the quantification of positive cells in every sample, as previously described [17].

**Western blot analysis**

Proteins of lungs tissues or cells were extracted with RIPA buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid disodium, 10% glycerol, 2% Triton X-100, and a protein inhibitor mixture [Beyotime Biotechnology, Shanghai, China]). For immunoblot analysis, 30 μg solubilized protein was loaded and resolved by sodium dodecyl sulphate polyacrylamide gel electrophoresis on 8% –15% gels. The proteins were then transferred to polyvinylidene difluoride (PVDF) membranes, blocked with 5% skim milk in PBS/Tween-20 for 1 h, and incubated with primary antibodies targeting phospho-Janus kinase 1 (P-JAK1) (D7N4Z , Cell signaling Technology), P-JAK2 (3771, Cell signaling Technology), P-STAT6 (ab263947, Abcam) and GAPDH (MAB5465, MultiSciences Biotech) overnight at 4 °C. Membranes were then washed and incubated with secondary HRP-labelled anti-rabbit/anti-mouse antibodies (1:5,000). Chemiluminescent images of the blots were captured using a ChemiDoc System. Image J software was used to calculate the integrated absorbance (IA) of the identified bands, and the expression of each protein was calculated using the following formula: Relative protein expression = IA<sub>protein</sub>/IA<sub>β-actin</sub> [23].

**Primary pulmonary mast cell culture and treatment**

Primary pulmonary mast cells were derived from the lungs of 4-week-old mice as previously described [24, 25]. In brief, lung samples were cut into pieces, dissociated by collagenase (50 U/mL in Hanks’ balanced salt solution), and filtered through a 40μm filter. The cells were cultured in Dulbecco’s modified medium (Gibco Invitrogen, U.S.A) containing 10% fetal bovine serum (Gibco). Mast cells were confirmed via flow cytometric analysis of surface markers, CD117 (553869; BD, CA) and FceRI (11-5898; eBioscience, CA). The cells were seeded in six-well plates at a density of 1 × 10<sup>6</sup> cells/mL, and 20ng /mL IL-4 (R&D Systems) was simultaneously applied for 1 and 4 h. Then the cells were collected for testing [26, 27].

**Co-immunoprecipitation**

Immunoblotting was performed as previously described [28, 29]. The cells were harvested in a cell lysis buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM MgCl<sub>2</sub>, 0.5% Triton X-100, 10 mM dithiothreitol, and protease/phosphatase inhibitor cocktails). Cell extracts were then incubated with 2 mg P-STAT6 antibody and 20 mg LProteinA/G at 4°C for 3 h. After the immunoprecipitation reaction, the samples were centrifuged at 4°C 3,000 rpm for 5 min, and then wash thrice. Finally, the proteins were eluted with elution buffer and boiled for 5 min prior to Western blot analysis. The PVDF membranes were blocked with a
solution containing primary antibodies against Tespa1. A control lacking the primary antibodies was incubated with anti-mouse IgG.

**Statistical analysis**

The data are reported as the mean ± S.D. Statistical significance was determined by ANOVA followed by Tukey’s correction for multiple comparisons or Student’s two-tailed t test for independent means. Non-parametric analyses were performed using Kruskal-Wallis one-way analysis. Pearson correlation (r) was used for correlation analysis. All analyses were performed using SPSS 11.0 for Windows (SPSS) software. P values less than 0.05 were considered statistically significant.

**Results**

**The expression level of Tespa1 mRNA in the sputum of asthmatic patients was lower and IgE level was higher than that of healthy controls**

To detect the role of Tespa1 in the pathogenesis of asthma patients, we selected sputum from 33 patients with chronic asthma and 36 healthy individuals to test the expression of Tespa1 mRNA and IgE levels. Results showed that compared with the healthy people, the level of Tespa1 mRNA expression of asthma patients was relatively lower, and IgE levels in the sputum of the patients were significantly increased (P < 0.05) (Fig. 1).

**OVA-induced asthma is more serious in Tespa1/- mice than in WT mice**

To further explore the role of Tespa1 in asthma, we assessed the OVA-induced asthma models of Tespa1/- and WT mice. Airway function was assessed by measuring the changes in lung resistance and compliance elicited by acetylcholine inhalation, which induced bronchoconstriction. The airway resistance for each of the four groups was analyzed, and the results are shown in Fig. 2. Airway resistance increased in OVA-primed/challenged mice from the Tespa1/- and WT groups compared with the control mice. Airway resistance increased in Tespa1/- mouse model compared with the WT mice. Pathology results proved the more evident inflammation in Tespa1/- asthma mice than in WT mice. Moreover, PAS dyeing results indicated that the distribution of goblet cells was more intensive in the small bronchial of Tespa1/- asthma mice than that in the WT group (Fig. 3A, 2B, 2C).

**KO of Tespa1 enhanced lung mast cell activity**

The results of toluidine blue staining of lung tissues showed that OVA induced an increase in the distribution of mast cells in the lungs of mice, and the Tespa1/- model mice showed more numerous compared with that in WT mice. Immunohistochemical analysis results showed that OVA could induce the increase in mast cell tryptase, a marker of mast cell activity, and this increase was more notable in Tespa1/- mice than in WT mice (Figs. 3A, 3D, and 3E).
KO of Tespa1 can reduce the activity of STAT6 pathway in asthma mice

Immunofluorescence results showed that OVA could induce the expression of P-STAT6. In Tespa1 KO mice, the increased expression of P-STAT6 was more remarkable compared with that in WT mice. ELISA was used to detect the changes in IL-4 and IL-13 levels to further verify the changes in the IL4/STAT6 signaling pathway. The results showed that the Tespa1−/− mouse model exhibited increased expressions of IL-4 and IL-13 than the WT mouse model. Western blot analysis results showed that OVA enhanced P-JAK1, P-JAK2, and P-STAT6 protein expression levels in Tespa1+/- and WT mice. P-JAK1 and P-STAT6 protein expression levels significantly increased in the Tespa1−/− mouse model compared with the WT model (Fig. 4).

Mast cell activity and IL4/STAT6 pathway are closely related to Tespa1

To investigate the role of Tespa1 on IL4/STAT6 pathway in mast cells, we stimulated lung mast cells with IL-4 in vitro. Results showed that tryptase activity significantly increased in Tespa1+/- mice than in the WT after IL-4 stimulation (Fig. 5). Moreover, co-expression results of P-STAT6 and Tespa1 showed that IL-4 stimulated the increased and decreased expressions of P-STAT6 and Tespa1, respectively. In addition, a negative correlation was observed between Tespa1 and P-STAT6 in mast cells, as proven by the correlation analysis (P < 0.01). Furthermore, immunoprecipitation results showed that P-STAT6 and Tespa1 are closely linked (Figs. 6).

Discussion

Tespa1 plays an important role in T cell development and negatively regulates FcεR1-mediated mast cell activation and allergic reactions [13, 30]. The regulation of Tespa1 on mast cells is related to the negative regulation of the IL-4/STAT6 signaling pathway. This study provides a new perspective into the mechanism of asthma progression.

The analysis of Tespa1 mRNA expression in clinical samples including normal individual and asthmatic patients, showed that Tespa1 gene expression was lower, and IgE levels are higher in asthmatic patients, suggesting a relationship between Tespa1 and asthma.

Tespa1−/− mice were used for further in vivo experiments to extensively study the relationship between Tespa1 and the incidence of asthma. Results showed that Tespa1−/− mice experienced more evident OVA-induced asthma attacks, which were manifested as increased airway resistance, increased inflammation and increased goblet cells. Toluidine blue staining showed that KO Tespa1 gene could increase the number of mast cells. Immunohistochemistry indicated that the activity of tryptase, a marker of mast cell activity [31, 32], is more reactive in Tespa1−/− asthmatic lungs than in WT mice, suggesting that Tespa1 could negatively regulate the aggregation and activation of mast cells. Hence, Tespa1 is associated with the proliferation and activation of mast cells in asthmatic mice. To further determine the role of Tespa1 in mast cells, we performed in vitro studies and observed that tryptase activity induced by IL-4 in Tespa1−/− mast cells was evidently enhanced compared with in WT cells, indicating that Tespa1 caused a certain inhibitory effect on mast cell activity.
The increased number and activity of mast cells mainly cause asthma, which involves many signaling pathways, in which the role of IL-4 /STAT6 pathway in mast high sensitivity has been studied [33, 34]. The abnormality of STAT6 is closely related to allergic diseases. Moreover STAT6−/− and IL-4−/− mice yield similar phenotypes, and cannot induce Th2 production, nor produce normal amounts of IgE, or even CD23, and IL-4 receptor subunit alpha [35–37]. Moreover, the hyperactivity of the IL-4 /STAT6 pathway is associated with asthma and chronic obstructive pulmonary disease, and the transcriptional inhibitors of this pathway are potential targets for the prevention and treatment of diseases caused by the hyperactivity of the IL-4 /STAT6 pathway [38, 39].

To study the effect of Tespa1 on STAT6 pathway, we detected the changes in IL-4 and IL-13 in the BALF of asthmatic mouse model, and the results showed that IL-4 and IL-13 in Tespa1−/− mice significantly increased compared with those in the WT asthma group. And level of P-STAT6 expression also increased, further indicating the negative regulatory effect of Tespa1 on the STAT6 signaling pathway. The STAT6 signaling pathway can be regulated by IL-4 /JAK1 and IL13/JAK2 [33, 40]. Western blot analysis results of lung tissues showed that in Tespa1−/− asthma mice, the phosphorylation level of JAK1 increased, but the increase in P-JAK2 level was negligible, indicating that Tespa1 mainly regulates the IL-4 /JAK1 signaling pathway. Experiments showed that tryptase activity increased in Tespa1−/− mast cell compared to with that WT in vitro, indicating that Tespa1 could negatively regulate the activation of mast cells. In addition, after IL-4 stimulation, the expression of P-STAT6 increased, whereas that of Tespa1 decreased. Thus, a negative correlation exists between P-STAT6 and Tespa1. When further exploring the relationship between Tespa1 and STAT6, immunoprecipitation results showed that Tespa1 and STAT6 directly interacted with each other.

**Conclusion**

In this study, experiments have confirmed that Tespa1 negatively regulates mast cells during asthma, and this event is related to the IL-4 /STAT6 signaling pathway. Thus, Tespa1 may be a potential target for asthma prevention and treatment. However, two deficiencies were identified. First, the exact mechanism of Tespa1 in regulating STAT6 still needs further study. Second, Tespa1 expression was also weakened after STAT6 signal activation. Hence, whether a cross-talk network exists between Tespa1 and IL-4 /STAT6 signaling pathway is unclear.

**Declarations**

**Ethical Approval and Consent to participate**

The use of the specimens was in accordance with the Declaration of Helsinki. This study was approved by the Animal Research Ethics Board of the Lishui University (Lishui, Zhejiang Province, China. Permit Number: 0901-2018).

**Consent for publication**
Not applicable.

**Availability of supporting data**

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.

**Funding**

This work was supported by grants from the National Natural Science Foundation of China (No. 81570013), Natural Science Foundation of Zhejiang province, China (NO. LY20H310007, LY17H100001), and Zhejiang University Student Science and Technology Innovation Activity Plan (New Talent Program) (NO. 2019R434018).

**Authors' contributions**

S.Q.W., R.H.Y. and L.R.L supervised and interpreted the experimental results and wrote the manuscript. R.H.Y. and L.Y. L. designed and performed the animal experiments. H.H.J., M.Z.Z., G.L.W. performed the animal experiments and analyzed the data. All authors reviewed the final manuscript.

**Acknowledgements**

None

**Competing interests**

The authors declare no competing financial interests.

**References**

1. Cecilia A, Ellen T, Zuzana D, Leif B. Revisiting the role of the mast cell in asthma. Current Opinion in Pulmonary Medicine. 2016;22:10–7.

2. Sebastian R, Michael S, Christian T. Mast cells in allergic asthma and beyond. Yonsei Medical Journal 2010, 51.

3. Turner H, Kinet J. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature. 2014;402:B24.

4. Galli SJ, Mindy T. IgE and mast cells in allergic disease. Nat Med. 2012;18:693.

5. Berings M, Gevaert P, De NR, Derycke L, Holtappels G, Pilette C, Bachert C, Lambrecht BN, Dullaers M. FceRI expression and IgE binding by dendritic cells and basophils in allergic rhinitis and upon
allergen immunotherapy. Clinical & Experimental Allergy Journal of the British Society for Allergy & Clinical Immunology 2018, 48.

6. Cong J, Shelburne CP, Guojie L, Potts EN, Riebe KJ, Sempowski GD, Michael W, Abraham F. SN: Particulate allergens potentiate allergic asthma in mice through sustained IgE-mediated mast cell activation. Journal of Clinical Investigation. 2011;121:941–55.

7. Voehringer D. Regulation and Function of Basophil, Eosinophil, and Mast Cell Responses. 2016.

8. Brown MA, Pierce JH, Watson CJ, Falco J, Ihle JN, Paul WE. B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell. 2016;50:809–18.

9. Strait RT, Morris SC, Smiley K, Jr UJ, Finkelman FD. IL-4 exacerbates anaphylaxis. J Immunol. 2003;170:3835–42.

10. Chen BL, Chen YQ, Ma BH, Yu SF, Li LY, Zeng QX, Zhou YT, Wu YF, Liu WL, Wan JB, et al. Tetrahydrocurcumin, a major metabolite of curcumin, ameliorates allergic airway inflammation by attenuating Th2 response and suppressing the IL-4Ralpha-Jak1-STAT6 and Jagged1/Jagged2-Notch1/Notch2 pathways in asthmatic mice. Clin Exp Allergy. 2018;48:1494–508.

11. Sherman MA, Secor VH, Lee SK, Lopez RD, Brown MA. STAT6-independent production of IL-4 by mast cells. Eur J Immunol. 2015;29:1235–42.

12. Wang D, Zheng M, Lei L, Ji J, Yao Y, Qiu Y, Ma L, Lou J, Ouyang C, Zhang X. Tespa1 is involved in late thymocyte development through the regulation of TCR-mediated signaling. Nat Immunol. 2012;13:560.

13. Di W, Mingzhu Z, Yuanjun Q, Chuansheng G, Jian J, Lei L, Xue Z, Jingjing L, Jun L, Wei H. Tespa1 negatively regulates FcεRI-mediated signaling and the mast cell-mediated allergic response. J Exp Med. 2014;211:2635–49.

14. Yun J, Duan F, Liu L, Chen X, Liu J, Luo Q, Wu J. A selective and sensitive nanosensor for fluorescent detection of specific IgEs to purified allergens in human serum. RSC Adv. 2018;8:3547–55.

15. Wang Q, Li H, Yao Y, Lu G, Wang Y, Xia D, Zhou J. HB-EGF-Promoted Airway Smooth Muscle Cells and Their Progenitor Migration Contribute to Airway Smooth Muscle Remodeling in Asthmatic Mouse. Journal of Immunology 2016, 196.

16. Wang J, Li FS, Pang NN, Tian G, Jiang M, Zhang HP, Ding JB. Inhibition of Asthma in OVA Sensitized Mice Model by a Traditional Uygur Herb Nepeta bracteata Benth. 2016, 2016:1–8.

17. Wu S, Yang R, Wang G. Anti-asthmatic effect of pitavastatin through aerosol inhalation is associated with CD4 + CD25 + Foxp3 + T cells in an asthma mouse model. Sci Rep. 2017;7:6084.

18. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng D, Pope J: Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology 2011, 27:635–662.

19. Lan X, Dong XW, Shen LL, Li FF, Jiang JX, Rui C, Yao HY, Shen HJ, Yun S, Xie QM. Simvastatin delivery via inhalation attenuates airway inflammation in a murine model of asthma. Int Immunopharmacol. 2012;12:556–64.
20. Sullivan P, Stephens D, Ansari T, Costello J, Jeffery P. Variation in the measurements of basement membrane thickness and inflammatory cell number in bronchial biopsies. Eur Respir J. 1996;12:811–5.

21. Guest IC, Stewart S. Bronchial lesions of mouse model of asthma are preceded by immune complex vasculitis and induced bronchial associated lymphoid tissue (iBALT). Lab Invest. 2015;95:886–902.

22. Han ES, Oh JY, Park HJ. Cordyceps militaris extract suppresses dextran sodium sulfate-induced acute colitis in mice and production of inflammatory mediators from macrophages and mast cells. J Ethnopharmacol. 2011;134:703–10.

23. Yang R, Song Z, Wu S, Wei Z, Xu Y, Shen X. Toll-like receptor 4 contributes to a myofibroblast phenotype in cardiac fibroblasts and is associated with autophagy after myocardial infarction in a mouse model. Atherosclerosis. 2018;279:23–31.

24. Lukacs NW, Kunkel SL, Strieter RM, Evanoff HL, Kunkel RG, Key ML, Taub DD. The role of stem cell factor (c-kit ligand) and inflammatory cytokines in pulmonary mast cell activation. Blood. 1996;87:2262–8.

25. Tomioka M., Goto T, Lee, Bienenstock TD, Befus J. AD: Isolation and characterization of lung mast cells from rats with bleomycin-induced pulmonary fibrosis. Immunology. 1989;66:439–44.

26. Patel KR, Aven L, Shao F, Krishnamoorthy N, Duvall MG, Levy BD, Ai X. Mast cell-derived neurotrophin 4 mediates allergen-induced airway hyperinnervation in early life. Mucosal Immunol. 2016;9:1466–76.

27. Wang Z, Guhl S, Franke K, Artuc M, Zuberbier T. IL-33 and MRGPRX2-Triggered Activation of Human Skin Mast Cells—Elimination of Receptor Expression on Chronic Exposure, but Reinforced Degranulation on Acute Priming. Cells, 8.

28. Yuan X, Hu T, He H, Qiu H, Wu X, Chen J, Wang M, Chen C, Huang S. Respiratory syncytial virus prolifically infects N2a neuronal cells, leading to TLR4 and nucleolin protein modulations and RSV F protein co-localization with TLR4 and nucleolin. J Biomed Sci. 2018;25:13.

29. Arsic N, Ho-Pun-Cheung A, Lopez-Crapez E, Assenat E, Jarlier M, Anguille C, Colard M, Pezet M, Roux P, Gadea G. Correction: The p53 isoform delta133p53ß regulates cancer cell apoptosis in a RhoB-dependent manner. Plos One. 2017;12:e0175607.

30. Liang J, Lyu J, Zhao M, Li D, Zheng M, Fang Y, Zhao F, Lou J, Guo C, Wang L. Tespa1 regulates T cell receptor-induced calcium signals by recruiting inositol 1,4,5-trisphosphate receptors. Nat Commun. 2017;8:15732.

31. Cahill KN, Katz HR, Cui J, Lai J, Kazani S, Crosby-Thompson A, Garofalo D, Castro M, Jarjour N, Dimango E: KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. New England Journal of Medicine 2017, 376:1911.

32. Tanaka RD, Clark JM, Warne RL, Abraham WM, Moore WR. Mast cell tryptase: a new target for therapeutic intervention in asthma. Int Arch Allergy Immunol. 1995;107:408–9.

33. Madden KB, Whitman L, Sullivan C, Gause WC, Urban JF, Katona IM, Finkelman FD, Sheadonohue T. Role of STAT6 and Mast Cells in IL-4- and IL-13-Induced Alterations in Murine Intestinal Epithelial Cell...
34. Sherman MA, Powell DR, Brown MA. IL-4 induces the proteolytic processing of mast cell STAT6. J Immunol. 2002;169:4417–22.

35. Elisabeth M, Albert D, Jutta HH. STAT6-dependent and -independent mechanisms in Th2 polarization. Eur J Immunol. 2012;42:2827–33.

36. Robinson MJ, Prout M, Mearns H, Kyle R, Camberis M, Forbes-Blom EE, Paul WE, Allen CD, Le GG. IL-4 Haploinsufficiency Specifically Impairs IgE Responses against Allergens in Mice. J Immunol. 2017;198:1815–22.

37. Chen M-H, Huang M-T, Lee S-S, Wang J-H, Cheng T-JR, Bowman MR, Hsieh S-L. Antibody blockade of Dectin-2 suppresses house dust mite-induced Th2 cytokine production in dendritic cell- and monocyte-depleted peripheral blood mononuclear cell co-cultures from asthma patients. J Biomed Sci. 2019;26:1–12.

38. Nofziger C, Vezzoli V, Dossena, Sch?Nherr S, Studnicka T, Nofziger J, Vanoni J, Stephan S, Silva S, Meyer ME. STAT6 links IL-4/IL-13 stimulation with pendrin expression in asthma and chronic obstructive pulmonary disease. Clin Pharmacol Ther. 2011;90:399–405.

39. Goenka S, Kaplan MH. Transcriptional regulation by STAT6. Immunol Res. 2011;50:87–96.

40. Ford D. Induction of the IL-13 receptor [alpha]2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways. Oncogene. 2001;20:6660.

41. Lee MY, Ahn KS, Kwon OK, Kim MJ, Kim MK, Lee IY, Oh SR, Lee HK. Anti-inflammatory and anti-allergic effects of kefir in a mouse asthma model. Immunobiology. 2007;212:647–54.

42. Myou S, Leff AR, Myo S, Boetticher E, Tong J, Meliton AY, Liu J, Munoz NM, Zhu X. Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT. J Exp Med. 2003;198:1573–82.

Figures
Figure 1

Tespa1 mRNA expression and IgE content in sputum of asthmatic and normal individuals. (A). The relative mRNA expression level of Tespa1 expressed as the ratio of the mRNA level of the target gene to the mRNA levels of the β-actin gene in sputum. (B). IgE levels in sputum of asthmatic and normal individuals. Results are expressed as mean ± SD. Control: healthy people (n = 36). Asthma: patients with asthma (n = 33). ##, P<0.01 comparison between the two groups.
Effect of Tespa1 on acetylcholine-induced airway hyperresponsiveness (AHR) in asthmatic mice. Airway resistance measurements were performed using a FinePointe RC system. The mice were challenged with aerosolized PBS (baseline) before treatment with acetylcholine at the following ascending doses: 0, 1, 2, 4, 8, and 16 mg/mL. KO: Tespa1-/- mice; WT: wild-type mice. The data are expressed as mean ± SD (n= 9 per group). **, P<0.01 compared with the WT control group; #, P<0.01 compared with the WT model group; ##, P<0.01 compared with the WT model group.
Figure 3

OVA-induced lung histological and tryptase changes in Tespa1-/- and WT mice as determined by H&E staining, PAS staining, toluidine blue staining, and immunohistochemistry. (A) Images of H&E staining, PAS staining, toluidine blue staining and immunohistochemistry. (B) Quantitative analysis of the degree of inflammatory cell infiltration in the lung sections, based on the methods developed by Myou and Lee [41, 42]. (C) Kruskal-Wallis one-way analysis of mucus production in the lung sections was performed in accordance with the methods developed by Myou and Lee. (D) Number of mast cells in lung slices. (E) Immunohistochemical scores of trptase. *P < 0.01 between groups. **P < 0.01 between groups. Mean ± SD, n= 8–10 mice per group.
Figure 4

OVA-induced changes in the protein expression of the IL-4/STAT6 signaling pathway in Tespa1-/- and WT mice, as determined by Western blot, ELISA, and immunofluorescence technique. (A) Electrophoretograms of proteins of P-JNK1, P-JNK2, P-STAT6 and GAPDH. (B) Graph of the relative protein expressions of P-JNK1, P-JNK2, and P-STAT6 as determined by Western blot analysis. (C) Quantitative analysis of IL-4 and IL-13 levels in the BALF of mice by ELISA. (D) Immunofluorescence staining for P-STAT6. (E) Table of average P-STAT6 fluorescence intensities. ** P < 0.01 between groups. * P < 0.05 between groups. Mean ± SD, n = 8-10.
Figure 5

Tryptase expression in the mast cells of Tespa1-/− and WT mice after IL-4 stimulation (A) Immunofluorescence staining for P-STAT6. (B) Table of average tryptase fluorescence intensities. ** P < 0.01 between groups. Mean ± SD, n = 10.

Figure 6

Tryptase expression in the mast cells of Tespa1-/− and WT mice after IL-4 stimulation and Relationship between Tespa1 and P-STAT6 detected by immunofluorescence and co-immunoprecipitation. (A) Immunofluorescence staining for Tespa1 and P-STAT6 after IL-4 stimulation. (B) Table of average Tespa1 and P-STAT6 fluorescence intensities. (C) Correlation analysis of Tespa1 and P-STAT6 expression of A. (D) Co-immunoprecipitation analysis of the relationship between Tespa1 and P-STAT6 in mast cells. ** P < 0.01 compared with P-STAT at 0 min; ## P < 0.01 compared with Tespa1 at 0 min. Mean ± SD, n = 10.